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NEURODEGENERATIVE DISEASE 
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Pathological tau disrupts the association between nitric oxide (NO) synthase and 
PSD95, impairing NO signalling and neurovascular coupling before causing 
neurodegeneration.  Stopping production of pathological tau rescues NO signalling, 
neurovascular coupling and neuronal function, but doesn’t remove tangles, 
suggesting that (like amyloid-β) soluble tau is an important driver of early 
neurovascular dysfunction and subsequent neuronal damage. 
 
Reducing the incidence of dementia and its impact on quality of life will require targeting 
interventions to the very early stages of the disease process, before substantial neuronal 
damage has occurred. We therefore need to know what goes wrong in the brain preclinically 
to cause the later cognitive decline. One early change is the dysregulation of cerebral blood 
flow, which may promote accumulation of the classic hallmarks of Alzheimer’s disease (AD), 
amyloid-β (Aβ) and tau, and subsequent neurodegeneration1. Park and colleagues2 now 
demonstrate a novel mechanism by which this may occur, whereby pathological tau reduces 
formation of the vasodilator nitric oxide (NO), and that suppressing pathological tau 
preserves NO production and improves cerebrovascular and cognitive function. 
 
Neuronal activity is energetically expensive, and disruption to the brain’s blood supply 
produces neurodegeneration-like changes1. Furthermore, cardiovascular disease and 
dementia share risk factors -- vascular pathology is often seen post mortem in the brains of 
patients with dementias, and decreased cerebral blood flow is observed in dementia 
patients1. Therefore, a decrease in the brain’s blood flow is thought to play a key role in the 
development of AD and other dementias such as frontotemporal dementia (FTD) 3,4. Indeed, 
changes in vascular function may even trigger neurodegenerative processes as they occur 
before accumulation of beta amyloid or cognitive decline in people who go on to develop 
AD5. One mechanism linking vascular function with neurodegeneration in AD is the 
interaction between blood vessels and Aβ, where Aβ is cleared from the brain across blood 
vessels1, but itself also constricts blood vessels, potentially slowing its own clearance6. This 
suggests a vicious cycle of impaired vascular function and Aβ accumulation that could lead 
to a neuronal energy crisis and neurodegeneration. But what about the other classic feature 
of AD, pathological tau? Tau is also involved in other dementias such as FTD, is better 
correlated with cognitive function than Aβ, and can also accumulate around blood vessels7,8. 
Here Park et al 2 show that tau, too, may play a critical role in dementia by impairing 
vascular function in early stages of the disease, before irreversible neuronal damage has 
occurred. 
 
To test how pathological tau affects neurovascular function, Park et al used mice that 
express a mutated version of tau (pathological tau) that causes familial FTD in humans and, 
in mice, aggregates to form tangles, neurodegeneration and cognitive deficits by 7-8 months 
of age 9. One important aspect of the study is that Park et al initially studied the effects of tau 
well before that stage, at 2-3 months, when such neuronal deficits were not yet present. 
They measured neurovascular coupling -- the increase in blood flow that occurs when 
neurons are activated -- by stimulating the whiskers and measuring blood flow and blood 
vessel diameter in the whisker barrel cortex. Small blood vessels (< 14 µm diameter) within 
the cortex dilated less and blood flow increased less in mice that expressed pathological tau. 
Application of recombinant pathological tau to the brains of wild-type mice produced the 
same deficits, confirming that the impairment in neurovascular coupling was due to mutated 
tau.   
 
Demonstrating a potential treatment window, this neurovascular coupling deficit was 
reversible and correlated with cognitive function. Using a different mouse model where tau 
expression was controlled by doxycycline, the authors showed that suppressing mutant tau 
expression from 3-4 months of age rescued the neurovascular coupling deficits observed 4 
months later in mice that continually expressed mutant tau. This recovery of neurovascular 
function was associated with a prevention, as previously reported 9, of the memory deficits 
and loss of brain tissue seen in 7-8 month old mice when pathological tau is not 
suppressed.  Crucially, the recovery of neurovascular and neuronal function occurred in the 
continued presence of neurofibrillary tangles, suggesting that soluble but not aggregated tau 
is the species driving both neurovascular and neuronal dysfunction9.  
 
So, these decreases in blood flow could be important for driving later neuronal and cognitive 
changes, but how does tau interfere with normal neurovascular coupling processes? A 
smaller blood flow response to whisker stimulation could be due to vascular cells being less 
able to dilate, neurons being less active during whisker stimulation, or a decrease in the 
signalling between neurons and the vasculature. Pathological tau did not reduce the ability 
of blood vessels to dilate, as acetylcholine (which directly stimulates vasodilation) produced 
the same increase in cerebral blood flow in mutant tau as wildtype mice. Neuronal activity 
was also unaffected by pathological tau at this age, as field potentials recorded in vivo during 
whisker stimulation, or increases in calcium in dissociated neurons in response to activation 
with N-methyl-D-aspartate (NMDA) were no different between WT and mice expressing 
mutant tau.  
 
Instead, Park et al found that signalling between neurons and blood vessels was reduced by 
pathological tau expression. In the healthy brain, one of the main signalling pathways that 
links neuronal activity to blood vessel dilation involves NMDA receptor-dependent activation 
of NO production.  Neuronal NO synthase (nNOS) is co-localised with NMDA receptors at 
the post-synaptic density as both proteins bind to the key anchoring protein, post-synaptic 
density protein 95 (PSD95). Calcium influx through NMDA receptors activates NO synthesis, 
and NO then diffuses to blood vessels where it causes them to dilate (see Figure) via 
production of cyclic guanosine monophosphate (cGMP), or in some cases by inhibition of the 
synthesis of the contractile molecule 20-hydroxyeicosatetraenoic acid (20-HETE)10. In 
mutant tau mice, however, the NMDA receptor/NO-dependent component of neurovascular 
coupling was absent. Blocking NMDA receptors or NO synthesis reduced the increase in 
blood flow in response to whisker stimulation but did not affect the residual blood flow 
response in mutant tau mice. Levels of NO produced by activating NMDA receptors were 
also reduced in these mice.  
 
These experiments suggest that pathological tau interferes with NMDA receptor-induced 
production of NO. How could this occur? Using immunoprecipitation to detect proteins bound 
to the scaffolding protein PSD95, Park et al found that pathological tau expression reduced 
nNOS binding to PSD95, while the association of PSD95 with the NMDA receptor subunit, 
GluN2B, was unchanged. Binding of nNOS to PSD95 was also blocked by tau in HEK cells 
which exogenously expressed mutated tau and nNOS. Thus, it is likely that pathological tau 
impedes NMDA receptor-mediated activation of NO synthesis by blocking binding of nNOS 
to the post-synaptic density. 
 
This study by Park et al therefore reveals a novel and potentially important mechanism 
whereby pathological tau can interfere with neurovascular function before 
neurodegeneration and cognitive impairments, via disruption of the association between 
PSD95 and nNOS, and post-synaptic production of NO (see Figure). It raises several new 
key questions about how tau pathology causes neurodegeneration.   
 
Physiologically, NO signals not only to blood vessels but to neurons, where it can be critical 
for synaptic plasticity and regulation of membrane excitability11,12. What, therefore, are the 
consequences for neuronal function of tau-mediated impairments in NO signaling? Are the 
interactions between PSD95 and any other proteins disrupted by soluble pathological tau, 
and therefore are there any NO-independent consequences of tau binding to PSD95? Do 
the observed neurovascular deficits cause neurodegeneration, or are they an 
epiphenomenon that might nonetheless serve as a useful marker for early tau-mediated 
changes in brain function? Finally, does pathological tau have the same effect in humans? 
Studies showing a lack of early cerebrovascular deficits in FTD patients carrying tau 
mutations suggest it may not, (unlike some other forms of FTD with non-mutated tau 4), 
though blood flow decreases are observed in these patients after cognitive changes have 
developed 13. 
 
Answering these questions will be vital for understanding the neurodegenerative process in 
FTD produced by tau mutations. It will also be important to discover if disruption of PSD95 
binding and NO signalling occur in other tauopathies, such as Alzheimer’s disease, where 
tau is not mutated, so levels and binding properties of the soluble protein may be different. 
Because tau phosphorylation is increased by hypoxia 14 such tau-mediated reductions in NO 
signalling could then form another strand in the web of factors linking early cerebrovascular 
dysfunction with progressive synaptic dysfunction and formation of classic Alzheimer’s 
disease plaques and tangles. For both AD and FTD, restoration of NO signalling could 
therefore also be considered a novel target for therapeutic intervention. 
 
By revealing this novel interaction between pathological tau and PSD95, and the consequent 
disruption of NO signalling to blood vessels (and presumably neurons), this study by Park et 
al reveals a new spoke in the wheel of factors linking pathological tau to neurodegeneration, 
providing new potential targets for intervention and opening a door to a wealth of new 
research directions. 
 
Figure: Neurovascular coupling under physiologic conditions and with tauopathy  
A: In normal physiologic conditions, glutamate release activates NMDA receptors in the post-
synaptic density. Neuronal nitric oxide synthase (nNOS) is associated with NMDA receptors via the 
scaffolding protein PSD95, so that calcium entering through NMDA receptors can activate NO 
synthesis from L-arginine. NO diffuses to local microvessels and dilates pericytes (the predominant 
vascular mural cell on vessels of this size15), increasing blood flow. White box with arrow indicates 
dilation from baseline vessel diameter. 
B: In mice that express a mutated form of tau, pathological tau reduces NO-mediated blood vessel 
dilation by binding to PSD95 and blocking its association with nNOS. NMDA receptor activation can 
no longer activate NO synthesis, reducing dilation of blood vessels, though neuronal activity can lead 
to residual vasodilation via other pathways. White box indicates baseline vessel diameter. 
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